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Abstract
Type I interferons (IFNs) are known to mediate viral control, and also promote survival and expansion of virus-specific CD8
+
T cells. However, it is unclear whether signaling cascades involved in eliciting these diverse cellular effects are also distinct.
One of the best-characterized anti-viral signaling mechanisms of Type I IFNs is mediated by the IFN-inducible dsRNA
activated protein kinase, PKR. Here, we have investigated the role of PKR and Type I IFNs in regulating viral clearance and
CD8
+ T cell response during primary and secondary viral infections. Our studies demonstrate differential requirement for
PKR, in viral control versus elicitation of CD8
+ T cell responses during primary infection of mice with lymphocytic
choriomeningitis virus (LCMV). PKR-deficient mice mounted potent CD8
+ T cell responses, but failed to effectively control
LCMV. The compromised LCMV control in the absence of PKR was multifactorial, and linked to less effective CD8
+ T cell-
mediated viral suppression, enhanced viral replication in cells, and lower steady state expression levels of IFN-responsive
genes. Moreover, we show that despite normal expansion of memory CD8
+ T cells and differentiation into effectors during a
secondary response, effective clearance of LCMV but not vaccinia virus required PKR activity in infected cells. In the absence
of Type I IFN signaling, secondary effector CD8
+ T cells were ineffective in controlling both LCMV and vaccinia virus
replication in vivo. These findings provide insight into cellular pathways of Type I IFN actions, and highlight the under-
appreciated importance of innate immune mechanisms of viral control during secondary infections, despite the accelerated
responses of memory CD8
+ T cells. Additionally, the results presented here have furthered our understanding of the
immune correlates of anti-viral protective immunity, which have implications in the rational design of vaccines.
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Introduction
Innate immunity constitutes the first line of anti-microbial host
defense and plays an important role in controlling the spread of
pathogens, before the onset of adaptive immunity [1]. Innate
immunity depends on immune cells such as macrophages, natural
killer (NK) cells, dendritic cells (DCs) and the cytokines produced
by them. Type I interferons (IFNs) are primary cytokines pro-
duced after viral infections, which induce an antiviral state in
neighboring cells by upregulating transcription of IFN-stimulated
genes (ISGs) [2,3]. Moreover, Type I IFNs are known to promote
CD8
+ and CD4
+ T cell responses by both direct and indirect
effects [4,5,6,7,8]. However, the signaling mechanisms underlying
the diverse cellular effects of Type I IFNs are not well understood.
One of the best-characterized anti-viral signaling mechanisms of
Type I IFNs is mediated by the IFN-inducible dsRNA activated
protein kinase, PKR [3,9,10]. PKR, an intracellular receptor for
dsRNA, is expressed ubiquitously at low levels as an inactive
kinase, and its transcription is upregulated by Type I IFN-
signaling. Binding of dsRNA produced during viral replication
alters the conformation of PKR, which leads to dimerization and
activation by autophosphorylation. Once activated, PKR phos-
phorylates the a-subunit of eukaryotic initiation factor 2 (eIF-2a)
to inhibit protein translation and suppress viral replication [11].
Not surprisingly, many viruses have evolved mechanisms to evade
the anti-viral effects of PKR [12,13,14,15]. In addition to the well-
known anti-viral actions, by way of its effects on translation and
transcription, PKR also regulates diverse processes including
cellular differentiation, proliferation, and apoptosis [11,16,17]. In
the immune system, PKR has been reported to mediate apoptosis
of macrophages, suppress translational response in T cells, and
downregulate T cell proliferation [18,19,20]. However, the role of
PKR in regulating T cell activation, effector differentiation or
function during an acute viral infection has not been investigated.
In addition to dsRNA and Type I IFNs, cellular PKR activation
can be triggered by exposure to immune regulatory cytokines like
IFN-c and TNF-a [21], and full activation of cells in response to
these cytokines is known to require PKR [22]. IFN-c and TNF-a
play non-redundant roles in governing the primary T cell
responses to lymphocytic choriomeningitis virus (LCMV) [23,24]
but a role for PKR in regulation of anti-viral T cell responses has
not been investigated.
The role of Type I IFNs in regulating anti-viral innate and
adaptive immune responses has been extensively studied using the
mouse model of LCMV. During a primary LCMV infection, Type
I IFNs play a non-redundant role in effecting early viral control,
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persistence [6,25,26]. Apart from their importance in innate
immunity to LCMV, direct effects of Type I IFNs are required for
activation and expansion of virus-specific CD8
+ T cells during a
primary response [5,6]. Moreover, diverse effects of Type I IFNs
on the activation and differentiation of dendritic cells during viral
infection can indirectly regulate anti-viral T cell responses [27].
However, it is yet to be determined whether cellular effects of
Type I IFNs in mediating LCMV control and/or CD8
+ T cell
activation during a primary infection include activation of PKR.
Additionally, the requirement for Type I IFNs in controlling viral
replication during secondary responses is unclear.
In this manuscript, we have determined: 1) the role of PKR in
viral control versus regulation of virus-specific CD8
+ T cell
responses during primary and secondary LCMV infection; 2) the
requirement for PKR in immune control of vaccinia virus in
vaccinated mice; 3) whether Type I IFNs contribute to LCMV
and vaccinia virus clearance during a secondary immune response.
These studies have not only allowed us to dissect the PKR-
dependent and independent signaling pathways of Type I IFN
actions during viral infections, they underscore the essential role
for innate immune mechanisms in controlling viral replication




LCMV control in PKR
2/2 mice
A considerable number of viruses have evolved mechanisms to
escape the antiviral effects of PKR, which illustrates its importance
in anti-viral innate immunity [15]. However, the effect of PKR
deficiency on LCMV control has not been reported. In order to
determine whether PKR deficiency affected LCMV replication,
wild type (+/+) and PKR-deficient (PKR
2/2) mice were infected
with LCMV, and viral titers in various organs were quantified at
days 2, 3, 5, 8, 15 and 30 post-infection (PI). Figure 1 shows that
up to day 3 PI, the LCMV titers in lung, liver, and spleen of
PKR
2/2 mice were comparable to those in +/+ mice. However,
between days 3 and 5 PI, differences in viral control emerged
between +/+ and PKR
2/2 mice. Viral titers slightly diminished
between day 3 and 5 PI in +/+ mice, whereas, LCMV titers in
liver and lungs increased by ,100-fold in PKR
2/2 mice during
the same interval. Thus, LCMV control at the onset of cellular
immunity is compromised in PKR
2/2 mice. In +/+ mice, a CD8
+
T cell response is detectable by day 5 PI and peaks on day 8 PI
[28]. The emerging virus-specific CD8
+ T cell response promptly
controls viral replication by day 8 to 10 PI [28]. Figure 1
illustrates that most of the +/+ mice controlled LCMV replication
to undetectable levels by day 8 PI. Strikingly, the majority of
PKR
2/2 mice harbored high viral loads in several tissues
examined at day 8 PI. However, by day 15 PI, most PKR
2/2
mice controlled infectious LCMV to levels that were below the
limit of detection, with no evidence of viral persistence thereafter.
Based on these results, we conclude that PKR plays an important
role in controlling LCMV replication in vivo.
Primary CD8
+ T cell responses against LCMV in PKR
2/2
mice
Data in Figure 1 showed that LCMV control was compro-
mised in PKR
2/2 mice. Here, we determined whether lack of
viral control in PKR
2/2 mice could be linked to the development
of an ineffective virus-specific CD8
+ T cell response. Moreover, we
were interested to determine whether Type I IFN-driven CD8
+ T
cell responses [6] to LCMV also required PKR. To this end, +/+
and PKR
2/2 mice were infected intraperitoneally (i.p.) with
LCMV. At day 8 PI, the number of LCMV-specific CD8
+ T cells
in spleen was quantitated by staining with MHC I tetramers
(Figure 2A). As shown in Figure 2A and 2B, the expansion of
LCMV-specific CD8
+ T cells at day 8 PI was significantly greater
in PKR
2/2 mice than in +/+ mice. Next, we examined the role of
PKR in regulating the functional attributes of LCMV-specific
effector CD8
+ T cells. As shown in Figure 2C, the MHC I-
restricted cytotoxic activity of epitope-specific CD8
+ T cells in
PKR
2/2 mice was comparable to those in +/+ mice. Further-
more, PKR deficiency did not affect antigen-triggered production
of IFN-c (Figure 2D) or TNFa (data not shown) by LCMV-
specific CD8
+ T cells. These data suggested that: 1) PKR is not
required for elicitation of the CD8
+ T cell response to LCMV; 2)
Lack of viral control in PKR
2/2 mice cannot be linked to a defect
in the anti-viral CD8
+ T cell response.
Impaired clearance of LCMV at day 8 PI in PKR
2/2 mice
(Figure 1) was surprising, because the virus-specific CD8
+ T cell
response appeared to be unaffected or even stronger in PKR
deficient mice. LCMV clearance by CD8
+ T cells is dependent
upon perforin-dependent MHC I-restricted cell-mediated cyto-
toxicity. It is therefore possible that PKR-deficient target cells may
be relatively resistant to cytotoxicity by CD8
+ T cells, which in
turn may impede viral control. To address this issue, we compared
the susceptibility of +/+ and PKR
2/2 splenocytes to cytotoxicity
using an in vivo CTL assay. Peptide-pulsed splenocytes from +/+
or PKR
2/2 mice were adoptively transferred into LCMV-infected
C57BL/6 mice, and in vivo lysis of the donor cells was assessed by
flow cytometry. As shown in Figure 2E, LCMV-specific effector
CD8
+ T cells lysed peptide-coated PKR
2/2 and PKR
+/+ target
cells similarly in vivo. It is also possible that PKR might regulate
the sensitivity of LCMV-infected cells to lysis by effector CD8
+ T
cells. To address this issue, we tested the susceptibility of LCMV-
infected primary bone marrow-derived dendritic cells (BMDCs)
from +/+ and PKR
2/2 mice to effector CD8
+ T cell-mediated
cytotoxicity in vitro. Data in Figure 2F show that LCMV-specific
effector CD8
+ T cells lysed LCMV-infected +/+ and PKR
2/2
Author Summary
Type I interferons (IFNs) constitute the first line of defense
against viral infections, promote antigen presentation by
dendritic cells, and play a crucial role in directly stimulating
anti-viral T cell responses. However, the mechanisms
underlying the diverse cellular effects of Type I IFNs are
not well defined. One of the best-characterized anti-viral
signaling mechanisms induced by Type I IFNs is mediated
by the IFN-inducible dsRNA activated protein kinase, PKR.
We show that requirement for cellular PKR activity could
be a distinguishing feature between Type I IFN actions that
mediate viral control or stimulate CD8
+ T cell expansion
during an acute infection with lymphocytic choriomenin-
gitis virus (LCMV). Typically, innate immune mechanisms
including Type I IFNs are considered important for viral
control during a primary infection. However, we find that
presence of vaccine-induced CD8
+ T cell memory and
accelerated generation of secondary effectors are neces-
sary but not sufficient to provide effective protective
immunity to re-infection, without the aid of innate
effectors PKR and Type I IFNs. These findings have
improved our understanding of virus-immune system
interactions and immune correlates of anti-viral protective
immunity, which might have implications in the develop-
ment of effective anti-viral vaccines and immunotherapies.
PKR and Type I IFNs in Innate and T Cell Immunity
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2/2 BMDCs was higher, as
compared to +/+ BMDCs (Figure 2F), which might be linked to
enhanced infection of PKR
2/2 cells by LCMV (see Figure 3B).
Taken together, we conclude that PKR deficiency does not appear
to affect sensitivity of peptide-coated or LCMV-infected target
cells to lysis by CD8
+ T cells.
Data in Figure 1 show that LCMV titers in PKR
2/2 mice but
not +/+ mice increased between days 3 and 5 PI, which coincides
with the initiation of the anti-LCMV T cell response. First, we
examined whether such an increase in viral titers occurred in
RAG1-deficient (RAG1
2/2) mice that lacks both B and T cells. As
shown in Figure S1, interestingly, viral titers increased between




between day 3 and 5 PI might be linked to delayed induction of
CD8
+T cell response.To addressthis issue, wequantitatedCD8
+T
cell response of +/+ and PKR
2/2 mice to LCMV at day 5 PI. Data
in Figure S2 show that LCMV-specific CD8
+ T cell response in
PKR
2/2 mice at day 5 PI was higher than in +/+ mice. Therefore,
it is unlikely that delayed development of CD8
+ T cell response
Figure 1. LCMV control in PKR
2/2 mice. +/+ and PKR
2/2 mice were infected with LCMV. Lungs, liver, and spleen from +/+ and PKR
2/2 mice were
collected at days 2, 3, 5, 8, 15, and 30 PI and the viral titers were determined by plaque assay. Each symbol (filled symbol is a +/+ mouse and open
symbol is a PKR
2/2 mouse) represents an individual mouse. The horizontal bar is the average titer of the group, and the dotted line is the limit of
detection. Data are from 2-6 independent experiments with 3–4 mice/group.
doi:10.1371/journal.ppat.1000966.g001
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2/2 mice.
However, a possibility still exists that CD8
+ T cells might require
PKR activity in infected cells to suppress cellular viral replication.
Further investigations will be required to determine whether viral
suppression by LCMV-specific CD8
+ T cells might occur less
efficiently in the absence of PKR activity in virally infected cells, at
least early in the infection.
Innate immune responses in PKR
2/2 mice
Data in Figure 1 and 2 showed that PKR
2/2 mice exhibit less
effective control of LCMV infection, despite the elicitation of a
potent CD8
+ T cell response. These findings suggested a role for
PKR in mediating at least some aspects of the innate response to
LCMV. It is well established that Type I IFNs play a critical role
in controlling LCMV replication early in the infection [6,25,26],
and it has been reported that both induction of Type I IFNs and
some of the antiviral effects of Type I IFN receptor signaling are
mediated via PKR [29]. Therefore, less effective viral control
might be due to lower production of Type I IFNs and/or a
reduction in the antiviral effects induced by Type I IFN receptor
signaling. To explore these possibilities, we examined whether
IFN-a production is affected by PKR deficiency during a LCMV
infection. As shown in Figure 3A, following an acute LCMV
infection, there was a substantial induction of IFN-a in the serum
of both +/+ and PKR
2/2 mice. The level of IFN-a peaked at
48 hours PI and tapered off thereafter in +/+ and PKR
2/2 mice.
Importantly, at all time points serum levels of IFN-a in PKR
2/2
mice were similar to those in +/+ mice. Thus, PKR deficiency did
not affect production of IFN-a during an acute LCMV infection.
Next, we determined whether lack of innate cellular resistance
to virus lead to enhanced LCMV replication in PKR-deficient
cells. BMDCs from +/+ and PKR
2/2 mice were infected with
LCMV and viral titers were quantitated at different time points
after infection. The kinetics of viral replication in PKR
2/2 cells
was similar to +/+ cells until 48 hrs. After 48 hours, however, viral
production by PKR
2/2 BMDCs was reproducibly higher, as
compared to +/+ DCs (Figure 3B) which suggested that LCMV
replication is enhanced in PKR
2/2 cells. Since the Type I IFN-
induced antiviral state is dependent at least in part on PKR, it is
possible that Type I IFN signaling-induced suppression of LCMV
replication is impaired in PKR
2/2 mice. Therefore, we deter-
mined whether PKR is required for Type I IFNs to effectively
suppress LCMV replication by comparing the viral titers in +/+
and PKR
2/2 cells pretreated with IFN-b in vitro. Primary
BMDCs from +/+ and PKR
2/2 mice were incubated for 20 to
24 hours with two different concentrations of IFN-b prior to
infection with LCMV; viral titers were determined at different
times after LCMV infection (Figure 3C). Pretreatment of cells
with IFN-b reduced viral titers in cultures of +/+ and PKR
2/2
BMDCs in a dose-dependent fashion. We compared the effects of
IFN-b on viral titers in +/+ and PKR
2/2 BMDCs by calculating
percent reduction in viral titers induced by IFN-b, relative to titers
in untreated cells (Figure 3C); note that linear and not log10 virus
titers were used for this calculation. Figure S3 illustrates the IFN-
b treatment -induced reduction in LCMV titers in +/+ and
PKR
2/2 BMDCs from two independent experiments. In both
experiments, IFN-b treatment led to a reduction in LCMV titers
in cultures of both +/+ and PKR
2/2 BMDCs. At 24, 48, and
72 hours after IFN-b treatment (10 U/ml), there were variable
and modestdifferences in viraltiter reduction(5–20%) between +/+
and PKR
2/2 BMDCs (Figure S3). However, at 96 hours after
IFN-b treatment, in both experiments, IFN-b-induced reduction
in viral titers in PKR
2/2 BMDCs was significantly (P,0.05)
lower, as compared to those in +/+ BMDCs. Viral titer reduction
by IFN-b treatment at a higher concentration (100 U/ml) was
comparable in +/+ and PKR
2/2 BMDCs. Thus, the anti-viral
effects of IFN-b are largely intact, but might be a little short-lived
in the absence of PKR (Figure S3). Additionally, the cell surface
expression of Type I IFN receptor was unaffected by PKR
deficiency (Figure S4). Treatment of +/+ BMDCs with IFN-c
also led to a modest reduction in virus titers with the effect much
less pronounced for BMDCs from PKR
2/2 mice (Figure 3D).
Taken together, these data suggested that: 1) PKR plays a role in
suppressing LCMV replication in infected cells; and 2) the
antiviral effects of Type I IFNs are largely intact, but might be
less sustained in PKR-deficient cells.
To further characterize the role of PKR in regulation of LCMV
replication, we quantitated the expression of IFN-regulated genes
with or without treatment with IFN-b. Data in Figure 3E show
that basal expression level of IFN-regulatory factors (IRFs) was 30
to 50% lower in BMDCs from PKR
2/2 mice than in +/+ mice.
This might explain the enhanced LCMV replication in PKR
2/2
BMDCs in vitro (Figure 3B). Treatment with IFN-b for 6 hours
led to comparable upregulation of transcripts for IRF1, IRF3,
IRF5, and IRF7 genes in +/+ and PKR
2/2 cells, as compared to
unstimulated cells (Figure 3F). Next we compared the levels of
the transcripts for these IFN-regulated genes in IFN-b-treated +/+
and PKR
2/2 cells. The transcript levels for IRF1, IRF3, and
IRF5, but not IRF-7 was ,50% lower in IFN-b-treated cells from
PKR
2/2 mice compared to IFN-b-treated BMDCs from +/+
mice (not shown). These findings show that PKR plays a positive
regulatory role in governing the cellular levels of ISGs in steady
state or even upon exposure to IFN-b.
Activation of natural killer cells (NK cells) constitutes an
important facet of innate immunity to virus infection. NK cells
typically are activated by Type I IFNs from day 2 to 5 after
Figure 2. Primary CD8
+ T cell responses in PKR
2/2 mice. +/+ and PKR
2/2 mice were infected intraperitoneally with LCMV, and virus-specific
CD8
+ T cell responses in spleen was assessed at day 8 PI. A. Splenocytes were stained with MHC class I tetramers, anti-CD8, and anti-CD44 antibodies.
The numbers in the dot plots are the percentages of tetramer positive CD8
+ T cells amongst splenocytes. The numbers in parenthesis are the
percentages of tetramer positive CD8
+ T cells of total CD8
+ T cells. B. Total numbers of epitope-specific tetramer-binding CD8
+ T cells in spleen. C.
Cytotoxic activity of CD8
+ T cells that are specific to the indicated epitopes was measured by a cytotoxicity assay directly ex vivo. The E:T represents
the ratio between splenocytes and peptide pulsed target cells (X axis) D. Antigen-triggered IFN-c production. IFN-c production by LCMV-specific
CD8
+ T cells was assessed by intracellular cytokine staining (ICCS) in vitro. The numbers on top are the percentages of IFN-c producing cells among
total splenocytes. The number in parenthesis is the mean fluorescent intensity (MFI) of IFN-c. E. The sensitivity of +/+ and PKR
2/2 target cells to CTL
activity was examined by in vivo CTL assay. Splenocytes (target cells) from +/+ and PKR
2/2 mice were uncoated or coated with GP33 peptide.
Uncoated target cells were labeled with a low concentration of CFSE, and GP33-coated target cells were labeled with a high concentration of CFSE.
High and low CFSE labeled target cells were mixed 1:1 and adoptively transferred into naı ¨ve (left) or LCMV-infected (day 8 PI) +/+ (right) recipient.
Five hours after cell transfer, the presence of donor cells in spleen was analyzed by flow cytometry; the number is the calculated percent specific lysis
of adoptively transferred target cells. F. Cell-mediated lysis of LCMV-infected BMDCs from +/+ or PKR
2/2 mice. Primary BMDCs derived from +/+ or
PKR
2/2 mice were infected with LCMV (1.0 MOI) and used as target cells for lysis by effector CD8
+ T cells from spleen of LCMV-infected C57BL/6 mice
(day 8 PI). The E:T represents the ratio between splenocytes (effectors) and LCMV-infected target cells (X axis). Data in this figure are representative of
two or more independent experiments with 3–4 mice/group.
doi:10.1371/journal.ppat.1000966.g002
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2/2 mice. A. +/+ and PKR
2/2 mice were infected with LCMV and serum samples were
collected at days 0, 1, 2, 3, and 5 PI (3–4 mice/group/time point). IFN-a levels in serum were measured using an ELISA kit. B. Triplicate cultures of
primary bone marrow-derived dendritic cells (BMDCs) from +/+ and PKR
2/2 mice were infected with LCMV at 0.01 MOI. The supernatants were
collected at the indicated time points and viral titers were determined by plaque assay. C. Triplicate cultures of primary BMDCs from +/+ and PKR
2/2
mice were pretreated with the indicated levels of IFN-b for 20 to 24 hours, then infected with LCMV at 0.01 MOI. The supernatants were collected at
the indicated time points and viral titers were determined by plaque assay. D. Triplicate cultures of BMDCs from +/+ and PKR
2/2 mice were left
untreated or pretreated with indicated doses of IFN-c for 20 to 24 hours, then infected with LCMV at 0.01 MOI. The supernatants were collected at
72 hours after infection and viral titers were determined by plaque assay. E. Steady state expression levels of IRF-1, IRF-3, IRF-5, and IRF-7 in BMDCs
from +/+ or PKR
2/2 mice. Real-time PCR was used to quantitate mRNA for the indicated IFN-responsive genes. The data are the quantities of mRNAs,
relative to expression levels of each gene in cells from +/+ mice. F. Expression of IRF-1, IRF-3, IRF-5, and IRF-7 in +/+ and PKR
2/2 IFN-b-treated BMDCs.
Relative quantities of mRNAs were calculated based on their expression levels in untreated BMDCs from respective +/+ or PKR
2/2 mice. G. NK cell
activity in the spleens of +/+ and PKR
2/2 mice (n=3) that were infected with LCMV three days before was measured by NK cell assay. Data in this
figure are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1000966.g003
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infection. Although NK cells are not required to clear LCMV
[30], it is possible that lower NK cell activity might facilitate
LCMV proliferation in PKR
2/2 mice. Here we determined
whether PKR is required for NK cells activation in vivo.
Figure 3G show that NK cells from both +/+ and PKR
2/2
mice lysed target cells efficiently. Thus, PKR is not required for
NK cell activation during an acute LCMV infection.
Secondary CD8
+ T cells responses and protective
immunity to LCMV in PKR
2/2 mice
Data in Figure 1 clearly illustrated that PKR is required for
normal viral clearance during a primary LCMV infection.
Although it is well established that innate immune mechanisms
are important in viral control during a primary infection, it is
unknown whether innate effectors like PKR are required for
efficient viral clearance during a secondary CD8
+ T cell response.
Therefore, we investigated the effect of PKR deficiency on
memory CD8
+ T cell-dependent LCMV control during a
secondary T cell response. Groups of +/+ and PKR
2/2 mice
were immunized with recombinant Listeria monocytogenes that
expressed the GP33 epitope of LCMV (rLM-GP33). Both +/+
and PKR
2/2 mice mounted a strong primary CD8
+ T cell
response to rLM-GP33; the number of GP33-specific CD8
+ T
cells at the peak of the primary response (day 7 PI) and memory
(day 90 PI) were similar in +/+ and PKR
2/2 mice (Figure 4A).
Thus, PKR deficiency did not affect the development of CD8
+ T
cell memory following immunization with rLM-GP33 in mice.
Next, we examined the importance of PKR in LCMV control
during a secondary CD8
+ T cell response. Groups of +/+ and
PKR
2/2 mice were immunized with rLM-GP33, and then
challenged with LCMV. Five days after LCMV challenge,
secondary expansion of GP33-specific CD8
+ T cells was assessed
in the spleens of +/+ and PKR
2/2 mice. Figure 4B shows that
GP33-specific CD8
+ T cells expanded to comparable levels in both
+/+ and PKR
2/2 mice. The absolute numbers of expanded
CD8
+ T cells were consistent between +/+ and PKR
2/2 mice
(Figure 4C). To assess whether GP33-specific memory CD8
+ T
cells differentiated into effectors in LCMV-challenged +/+ and
PKR
2/2 mice, we performed an in vivo CTL assay. The in vivo
CTL activity in the spleens of PKR
2/2 mice was undistinguish-
able from that in +/+ mice (Figure 4D). Consistent with potent
secondary expansion of CD8
+ T cells and effector activity, +/+
mice controlled LCMV effectively in both lung and spleen. In
striking contrast, PKR
2/2 mice exhibited poor LCMV control in
lung and spleen despite strong secondary CD8
+ T cell responses
(Figure 4E). Taken together, the data in Figures 1 and 4 show
that PKR is required for viral control during primary and
secondary CD8
+ T cell response to LCMV infection. Please note
that PKR
2/2 mice do control LCMV during a primary infection,
albeit after a delay of ,7 days (Figure 1). Therefore, it is expected
that potent secondary GP33-specific CD8
+ T cell responses in
LCMV-challenged rLM-GP33-immune mice would be able to
control LCMV without the establishment of viral persistence.
Viral control by TCR transgenic memory CD8
+ T cells in
PKR deficient mice
Data in Figure 4 show that PKR
2/2 mice immunized with
rLM-GP33 provided poor protective immunity against LCMV,
despite robust secondary CD8
+ CTL responses. One caveat to
these experiments is that the total number and quality of LCMV-
specific memory CD8
+ T cells (prior to LCMV challenge) in
PKR
2/2 mice could be lower than in +/+ mice. Alternatively, it is
possible that memory CD8
+ T cells generated in PKR
2/2 mice
might possess poor protective abilities. Furthermore, viral
clearance might be impaired in PKR
2/2 mice regardless of the
quality and the magnitude of the secondary CD8
+ T cell response,
due to deficiency of other factors involved in LCMV control. Here
we tested the hypothesis that PKR expression in non CD8
+ T cells
is required for memory CD8
+ T cell-dependent control of LCMV.
To test this hypothesis, we generated wild type monoclonal TCR
transgenic (tg) P14 LCMV-specific memory CD8
+ T cells in vivo
in a PKR-sufficient environment. Thy1.1 positive wild type GP33-
specific TCR tg P14 memory CD8
+ T cells were adoptively
transferred into cohorts of +/+ or PKR
2/2 mice, which were
subsequently challenged with LCMV (Figure 5A). Please note
that adoptively transferred P14 CD8
+ T cells are Thy1.1 positive
while T cells in the recipients are Thy1.2 positive. Five days after
challenge, the secondary expansion of donor P14/Thy1.1 memory
CD8
+ T cells and viral control were assessed in +/+ and PKR
2/2
mice. Donor P14 memory CD8
+ T cells expanded in both +/+
and PKR
2/2 recipient mice, and the total number of P14
memory CD8
+ T cells in spleen of PKR
2/2 mice was comparable
to those in +/+ mice (Figure 5B). Furthermore, secondary P14
effectors in +/+ and PKR
2/2 recipients showed downregulation
of CD127 and CD62L, and upregulation of CD43 expression
(Figure 5C). All donor P14 CD8
+ T cells in LCMV-challenged
+/+ or PKR
2/2 recipients were functional, readily produced IFN-
c upon ex vivo antigenic stimulation (Figure 5D), and also
expressed high levels of granzyme B (Figure 5E). In summary, the
adoptively transferred P14 CD8
+ T cells in PKR
2/2 mice were
comparable to those in +/+ mice based on number, cell surface
phenotype, and function. While 75% of +/+ mice cleared LCMV
to levels below the limit of detection, all PKR
2/2 mice uniformly
contained high levels of virus in the lung. The spleens of PKR
2/2
mice contained .100 fold greater levels of infectious LCMV than
in +/+ mice (Figure 5F). Thus, LCMV control by wild type P14
memory CD8
+ T cells was less efficient in a PKR-deficient
environment as compared to a PKR-sufficient environment.
However, as in a primary infection (Figure 1), LCMV-challenged
PKR
2/2 mice would be expected to achieve viral clearance, albeit
with a delay of ,1 week.
It has been reported that PKR might play a role in inducing the
expression of adhesion molecules, such as vascular cell adhesion
molecule (VCAM)-1, which controls immune cell migration [31].
To examine the possibility that P14/Ly5.1 T cell trafficking to the
infected sites might be defective in PKR deficient mice, lung
sections from P14 cell transferred +/+ and PKR
2/2 mice were
stained with anti-Ly5.1 antibody. In Figure 6, TCR tg donor
Ly5.1 positive P14 cells were detected in lungs of recipient +/+
and PKR
2/2 mice, but not in control mice that did not receive
P14 cells. The anatomical distribution and number of Ly5.1/P14
CD8
+ T cells in the lungs of PKR
2/2 mice was similar to those in
+/+ mice. These data suggested that PKR deficiency might not
affect trafficking of effector CD8
+ T cells to the site of infection.
Viral control by polyclonal PKR-deficient memory CD8
+ T
cells
Data in Figure 5F illustrates that P14 TCR tg memory CD8
+
T cells that express PKR controlled LCMV in +/+ and not in
PKR
2/2 mice. This finding suggested that PKR in non CD8
+ T
cells contributes to LCMV clearance. Here, we investigated
whether PKR expression in CD8
+ T cells regulates viral clearance
by LCMV-specific memory CD8
+ T cells. Groups of +/+ and
PKR
2/2 mice were infected with LCMV. At day 90 PI, we
quantitated the number of LCMV-specific memory CD8
+ T cells
in spleens of LCMV-immune +/+ and PKR
2/2 mice by using
PKR and Type I IFNs in Innate and T Cell Immunity
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studies showed that the total number of CD8
+ T cells specific to
the three dominant epitopes (NP396, GP33, and GP276) was ,2-
fold higher in PKR
2/2 mice than in +/+ mice (data not shown).
We also compared the relative proportions of central (CD62L
Hi)
and effector (CD62L
Lo) LCMV-specific memory CD8
+ T cells
between LCMV-immune +/+ and PKR
2/2 mice. The percent-
ages of effector memory cells amongst +/+ and PKR
2/2 memory
CD8
+ T cells ranged between 20–30% and 50–70% respectively
(Figure S5). The increase in the relative proportions of effector
memory CD8
+ T cells is likely linked to delayed viral clearance in
PKR
2/2 mice [32]. CD8
+ T cells were purified from the spleens
of LCMV-immune +/+ and PKR
2/2 mice, and the numbers of
memory CD8
+ T cells that are specific to the three dominant
epitopes were normalized by tetramer staining. Purified CD8
+ T
cells (containing equal number of LCMV-specific memory CD8
+
T cells) from +/+ or PKR
2/2 mice (Ly5.2) were adoptively
transferred into congenic Ly5.1/B6 mice, which were subsequent-
ly challenged with LCMV (Figure 7A). At 5 days after challenge,
we assessed the secondary expansion of donor CD8
+ T cells and
viral load in tissues. As shown in Figure 7B and 7C, the
secondary expansion of donor PKR
2/2 mice memory CD8
+ T
cells was comparable to +/+ memory CD8
+ T cells. Viral load in
recipient mice was compared to control mice that did not receive
memory CD8
+ T cells. As expected, control mice that were not
recipients of memory CD8
+ T cells harbored high levels of virus in
Figure 4. Primary and secondary CD8
+ T cell responses after Listeria monocytogenes immunization. A. +/+ and PKR
2/2 mice were
infected with rLM-GP33. At 7 and 90 days after infection, the numbers of GP33-specific IFN-c-producing CD8
+ cells were quantitated by intracellular
cytokine staining. B and C. At day 90 PI, LM-GP-immune +/+ and PKR
2/2 mice were challenged with LCMV. Five days after challenge, the number of
GP33-specific IFN-c-producing CD8
+ T cells was assessed by intracellular cytokine staining. Dot plots from representative mice (B) and the absolute
numbers of all mice (C) are shown. The horizontal bar in C is the average for each group. D. CTL activity of GP33-specific effector CD8
+ T cells in
spleen of LCMV-challenged +/+ and PKR
2/2 mice was measured by in vivo CTL assay at day 5. GP33-coated target cells (CFSE
high) or uncoated target
cells (CFSE
low) were transferred into uninfected or LCMV-challenged (Chal-D5) +/+ or PKR
2/2 mice. The number is the calculated percent specific lysis
of adoptively transferred target cells, and representative of data from 3–4 mice/group. E. Viral load in lung and spleen of LCMV-challenged +/+ or
PKR
2/2 mice at day 5. Each symbol represents an individual mouse; filled symbols are +/+ and open symbols are PKR
2/2 mice. Data in this figure are
representative of or derived from 2–8 independent experiments with 3–4 mice/group.
doi:10.1371/journal.ppat.1000966.g004
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CD8
+ T cells and PKR-deficient memory CD8
+ T cells reduced
the viral load by 10 to 100-fold, respectively, compared to control
mice (Figure 7D). Importantly, viral control by PKR
2/2
memory CD8
+ T cells was superior to +/+ memory CD8
+ T
cells, which suggested that PKR expression in memory CD8
+ T
cells is not required for LCMV control. The mechanisms
underlying the enhanced protection by PKR-deficient memory
CD8 T cells need further investigation. There is increasing
evidence that effector memory CD8
+ T cells confer better
protection than the central memory CD8
+ T cells [33,34,35,36].
Therefore, we speculate that larger number of effector memory
CD8 T cells present amongst the adoptively transferred memory
PKR
2/2 memory CD8
+ T cells led to enhanced LCMV control
in recipient mice. Taken together, the data in Figures 5 and 7
show that PKR expression in the infected cells, but not in CD8
+ T
cells, is important for effective viral control.




The results presented thus far (Figures 1, 4, and 5)
demonstrated that PKR is required for LCMV clearance during
primary and secondary infection in mice. PKR activity is induced
by Type I IFNs, and some of the antiviral activity of the Type I
IFNs could be PKR dependent (Figure 3C). We, therefore,
hypothesized that Type I IFN signaling is required for protection
against secondary LCMV infection, which could be, at least in
part, PKR dependent. In order to test this hypothesis, we took two
approaches: In the first set of experiments, we immunized +/+ or
Type I IFN receptor-deficient (IFNAR
2/2) mice with rLM-GP33,
which were challenged with LCMV (described in Figure 4).
GP33-specific memory CD8
+ T cells generated by immunization
with rLM-GP33 expanded similarly in +/+ or IFNAR
2/2 mice
following LCMV challenge (Figure 8). Figures 8A and 8B show
secondary expansion of GP33-specific CD8
+ T cells. The
Figure 5. Secondary expansion of TCR tg memory CD8
+ T cells in +/+ and PKR
2/2 mice. A. Experimental design. Thy1.1
+ve P14 memory
CD8
+ T cells (generated as described in Materials and Methods), were adoptively transferred into congenic Thy1.2/+/+, or Thy1.2/PKR
2/2 mice.
Following cell transfer, mice were challenged with LCMV, and secondary expansion of donor P14 CD8
+ T cells was assessed in spleen at day 5 after
challenge. B and C. Splenocytes from +/+ or PKR
2/2 were stained with D
b/GP33 MHC I tetramer and anti-Thy1.1; dot plots are gated on total
splenocytes, and the numbers are the percentages of P14 CD8
+ T cells amongst splenocytes. The total number of P14 cells (right panel in B)i s
calculated from 5 mice/group. C. Cell surface phenotype of donor P14 CD8
+ T cells in LCMV-challenged +/+ and PKR
2/2 mice; FACS plots are gated
on tetramer-binding P14 CD8
+ T cells. D. IFN-c production by donor P14 cells was quantitated by intracellular cytokine staining; dot plots are gated
on total splenocytes. E. Splenocytes from LCMV-challenged +/+ or PKR
2/2 mice were stained for cell surface Thy1.1/CD8 and intracellular granzyme B.
FACS histograms are gated on P14 CD8
+ T cells; dotted and solid lines represent staining with isotype control and anti-granzyme B antibodies
respectively. F. Viral titers in lung and spleen of LCMV-challenged +/+ or PKR
2/2 mice were determined by plaque assay. Each symbol represents an
individual mouse. Results are representative of or derived from 4 independent experiments with 3 to 5 mice per group.
doi:10.1371/journal.ppat.1000966.g005
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CD127 (the IL-7 receptor) were low, but the expression of KLRG-
1 (the NK cell receptor) was high on effector cells in +/+ mice
(Figure 8C). Notably, CD127 expression on effector CD8
+ cells
in IFNAR
2/2 mice was markedly higher (Figure 8C), as
compared to those in +/+ mice. Despite the comparable
expansion of GP33-specific T cells in both groups of mice, viral
control by GP33-specific effector cells in IFNAR
2/2 mice was
severely impaired (Figure 8D).
In a second series of experiments, we adoptively transferred
P14/Ly5.1 memory CD8
+ T cells into +/+ or IFNAR
2/2 mice,
which were subsequently challenged with LCMV. The secondary
expansion of donor P14/Ly5.1 CD8
+ T cells and viral control was
assessed as described above. Figure 9A shows that secondary
expansion of P14/Ly5.1 CD8
+ T cells was comparable in +/+ and
IFNAR
2/2 mice. The cell surface expression of CD43, CD62L,
and CD69 in +/+ recipients was similar to those in IFNAR
2/2
recipients. Interestingly, CD127 expression on P14 CD8
+ T cells
in IFNAR
2/2 mice was substantially higher than in +/+ mice
(Figure 9B), which is consistent with the result from rLM-GP33
immunization model. The IFN-c-producing ability and granzyme
B content of P14 CD8
+ T cells in IFNAR
2/2 mice was
comparable to +/+ mice (Figures 9C, D). Strikingly, despite
normal secondary CD8
+ T cell responses in IFNAR
2/2 recipients,
viral control was severely impaired; LCMV titers in IFNAR
2/2
recipients were at least 100,000-fold more compared to +/+ mice
at day 5 after challenge (Figure 9E). LCMV-challenged
IFNAR
2/2 continued to harbor high levels of virus at least until
day 8 after challenge. We were unable to assess viral clearance
thereafter because P14 cell-transferred LCMV-challenged IF-
NAR
2/2 mice succumbed to immunopathology within day 11
after challenge. Thus, Type I IFNs are essential for LCMV control
during a secondary LCMV infection.




Results presented in Figures 4, 5, 8 and 9 clearly
demonstrated the importance of PKR and Type I IFNs in
controlling LCMV replication during a secondary CD8
+ T cell
response. Primary control of vaccinia virus requires Type I IFNs,
but it is not known whether secondary CD8
+ T cell memory-
dependent control of vaccinia virus requires PKR and/or Type I
IFNs [37,38]. Therefore, we immunized groups of +/+, PKR
2/2,
and IFNAR
2/2 mice with rLM-GP33. At day 90 after rLM-GP33
immunization (Figure 10A), the number of GP33-specific
memory CD8+ T cells in PKR
2/2 and IFNRA
2/2 mice was
comparable to those in +/+ mice. Next, rLM-GP33-immune +/+,
PKR
2/2, and IFNRA
2/2 mice were challenged with recombi-
nant vaccinia virus that expresses the glycoprotein of LCMV (VV-
GP). At 5 days after challenge, the expansion of GP33-specific
CD8
+ T cells was assessed in the spleen. Figures 10B show
that the total number of GP33-specific CD8
+ T cells in PKR
2/2
and IFNAR
2/2 mice was comparable to those in +/+ mice.








high)( Figure 10C). Further-
more, GP33-specific CD8
+ T cells in PKR
2/2 and IFNAR
2/2
mice were capable of cytokine production and expressed high
levels of granzyme B (Figure 10D and 10E). PKR deficiency
alone did not appear to affect VV-GP control in lung and ovary.
By contrast, all IFNAR
2/2 mice uniformly exhibited impaired
VV-GP control in both lung and ovary (Figure 10F). These data
suggested that secondary control of vaccinia virus requires Type I
IFNs, and the dependency of viral control on PKR and/or Type I
IFNs is virus dependent.
Discussion
The immune response to infection is divided into 2 phases: the
early innate immune response and the later adaptive immune
response. The mechanisms of innate immunity provide incomplete
protection, but keep the pathogen in check until the more
definitive adaptive immunity develops. In recent years, there is
increased realization that mechanisms of innate immunity play a
key role in both the induction and effector phases of adaptive
immunity. In viral infections, Type I IFNs play a non-redundant
role in early innate immunity, and in induction of the anti-viral T
cell response [3,5,6,37]. The IFN-inducible protein kinase PKR is
a unique, multifunctional molecule that is known to act as a PRR
for dsRNA and to mediate several of the anti-viral effects of Type I
IFNs [9,39,40]. Additionally, PKR has been reported to regulate
cellular proliferation, differentiation, and apoptosis [21,41,42,43].
Figure 6. Trafficking of TCR tg P14 CD8
+ T cells into infected lungs in +/+ and PKR
2/2 mice. As in Figure 5, Ly5.1/P14 TCR tg memory CD8
+
T cells were adoptively transferred into +/+ or PKR
2/2 mice, which were subsequently challenged with LCMV. Five days after challenge, trafficking of
Ly5.1/P14 CD8
+ T cells into lungs was visualized by immunofluorescent staining with Alexa 568-conjugated anti-Ly5.1 antibodies (Red). Lung section
from a +/+ mouse that did not receive Ly5.1/P14 CD8
+ T cells is shown as a negative control. Multiple sections from each mouse were analyzed, and
results in this figure are representative of data from 3 to 4 mice per group.
doi:10.1371/journal.ppat.1000966.g006
PKR and Type I IFNs in Innate and T Cell Immunity
PLoS Pathogens | www.plospathogens.org 10 June 2010 | Volume 6 | Issue 6 | e1000966The non-redundant in vivo role of PKR as an innate anti-viral
defense mechanism or as a regulator of virus-specific T cell
response has not been examined. In the present study, we have
dissected the importance of PKR in Type I IFN-dependent T cell
regulation and cellular anti-viral defense during primary and
secondary immune responses. Our studies document that Type I
IFNs might exert their anti-viral and T cell regulatory effects by
stimulating cellular pathways, which are dependent and indepen-
dent of PKR respectively. We also provide strong evidence that
presence of CD8
+ T cell memory and accelerated generation of
secondary effectors is insufficient to provide effective protective
immunity to re-infection without the aid of innate effectors PKR
and Type I IFNs. These findings have implications in under-
standing virus-immune system interactions and immune correlates
of anti-viral protective immunity.
Upon infection with LCMV, both wild type and PKR
2/2 mice
developed potent and functional CD8
+ T cell response, but only wild
type mice were able to control viral replication by day 8 PI. Indeed, the
expansion of virus-specific CD8
+ T cells in PKR
2/2 mice was
reproducibly ,2-fold higher compared to PKR
+/+ mice. The
increased expansion of CD8
+ Tc e l l si nP K R
2/2 mice was not likely
due to higher viralload because during a chronic LCMV infection with
clone 13 strain, under conditions of similar viral load, the expansion of
CD8
+ T cell was higher in PKR
2/2 mice than in +/+ mice (data not
shown). Nevertheless, our data are consistent with a previous report
that PKR downregulates CD8
+ Tc e l lr e s p o n s ei nv i v oi nad e l a y e d
hypersensitivity model [20]. Previous work has shown that direct effects
of Type I IFNs are required for optimal clonal expansion, survival, and
differentiation of effector CD8+ T cells during an acute LCMV
infection [6]. Our studies show that dependency of CD8
+ T cells on
Figure 7. Secondary expansion of +/+ or PKR
2/2 memory CD8
+ T cells in Ly5.1/+/+ mice. A. Experimental design. Ly5.2/+/+ or Ly5.2/PKR
2/2
mice were infected with LCMV. At 90 days after LCMV infection, CD8
+ T cells were purified from spleens of LCMV-immune +/+ or PKR
2/2 mice. Total
CD8
+ T cells containing equal number of LCMV-specific memory CD8
+ T cells (NP396+GP33+GP276-specific) were adoptively transferred into congenic
C57BL/6/Ly5.1+/+ mice. The recipients were challenged with LCMV and the secondary expansion of donor LCMV-specific memory CD8
+ T cells was
assessed 5 days later. B and C. Antigen-triggered IFN-c production by donor Ly5.2
+ CD8




+ T cells in the recipient. D. The viral titer in spleen of LCMV-challenged mice that were recipients of +/+ or PKR
2/2 memory CD8
+ T cells was
quantitated by plaque assay; viral titer in mice that did not receive memory CD8
+ T cells are shown as controls. Each symbol indicates an individual
mouse and the horizontal bar is the average of the group. Results are representative of two independent experiments with 4 to 6 mice per group.
doi:10.1371/journal.ppat.1000966.g007
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might not include the requirement for PKR.
Defective LCMV control in PKR
2/2 mice cannot be attributed
to functional defects in virus-specific CD8
+ T cells because PKR
deficiency did not affect either the MHC-restricted cell-mediated
cytotoxicity or the ability of CD8
+ T cells to produce effector
cytokines like IFN-c and TNF-a directly ex vivo. PKR has been
reported to be required for apoptosis of immune cells like
macrophages [19]. Therefore, it is possible that LCMV-infected
cells in PKR
2/2 mice are more resistant to lysis by effector CD8
+
T cells. However, we find that defective LCMV clearance in
PKR
2/2 mice is not likely due to cellular resistance to lysis by
CD8
+ CTLs. Detailed analysis of the kinetics of LCMV replication
indicated that infectious LCMV levels between days 3 and 5 PI
was reduced by ,10 fold in wild type mice but increased by ,10
fold in PKR
2/2 mice between days 3 and 5 PI. This resulted
in a ,100 fold higher viral titer in PKR
2/2 mice compared to
PKR
+/+ mice at day 5 PI. Loss of viral control between days 3 and
5 PI in PKR
2/2 mice was similar to those in RAG1
2/2 mice,
which lack both B and T cells. These data indicated that delayed
development of CD8
+ T cell responses in PKR
2/2 mice might
underlie enhanced viral titers between days 3 and 5 PI. However,
CD8
+ T cell responses to LCMV in PKR
2/2 mice at day 5 PI
were indeed greater than in +/+ mice. These findings showed that
defective viral control in PKR
2/2 mice couldn’t be linked to
delayed emergence of anti-viral CD8
+ T cell response. Based on
these results, we propose that CD8
+ T cell-dependent viral
clearance early in the infection requires PKR activity in infected
cells. Further studies are warranted to identify the PKR-dependent
anti-viral effector functions of CD8
+ T cells.
Figure 8. Secondary expansion of GP33-specific CD8
+ T cells and viral control in +/+ and IFNAR
2/2 mice. +/+ or IFNAR
2/2 mice were
immunized with rLM-GP33. Sixty days after rLM-GP33 infection, mice were challenged with LCMV and GP33-specific CD8
+ T cell responses were
assessed in spleen five days later. A. The dot plots show expansion of GP33-specific CD8
+ T cells in +/+ and IFNAR
2/2 mice; the numbers are the
percentages of GP33-specific CD8
+ cells among total splenocytes. B shows total number of GP33-specific CD8
+ T cells in spleen of LCMV-challenged
+/+ and IFNRA
2/2 mice. C. Cell surface phenotype of GP33-specific CD8
+ T cells. Splenocytes from +/+ or IFNAR
2/2 mice were stained with antibodies
against CD62L, CD127, and KLRG-1 in conjunction with anti-CD8 and D
b/GP33 MHC I tetramers. Dot plots are gated on tetramer-binding CD8
+ T cells,
and the numbers are the percentages of CD62L
hi/low, CD127
hi/low, and KLRG-1
hi/low cells among tetramer-binding CD8
+ T cells. D. Viral titers of spleen,
lung, and liver from LCMV-challenged +/+ or IFNAR
2/2 mice were quantitated by plaque assay; each symbol indicates viral titer of an individual
mouse. Results are representative of two independent experiments, with 3 to 4 mice per group.
doi:10.1371/journal.ppat.1000966.g008
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dsRNA and ssRNA containing 59- triphosphate [44]. Interaction
with viral RNA leads to activation of PKR, which in turn regulates
various signaling pathways including induction of cytokines like
Type I IFNs. However, PKR deficiency did not affect production
of IFN-a or the activation of NK cells. One of the critical
Figure 9. Expansion of TCR tg P14 memory CD8
+ T cells and viral control in IFNAR
2/2 mice. As in Figure 5A, Ly5.1/P14 memory CD8
+ T
cells (generated as described in Materials and Methods), were adoptively transferred into congenic Ly5.2/+/+, or Ly5.2/IFNAR
2/2 mice; recipient mice
were challenged with LCMV and CD8
+ T cell responses were assessed five days later. A. Secondary expansion of donor P14 memory CD8
+ T cells. Dot
plots are gated on total splenocytes, and the numbers are percentages of donor Ly5.1 CD8
+ T cells among splenocytes; the accompanying bar graph
(right panel) shows total number of P14 CD8
+ T cells in spleen of +/+ and IFNRA
2/2 mice. B. Cell surface phenotype of donor P14 CD8
+ T cells.
Splenocytes from +/+ or IFNAR
2/2 recipients were stained with antibodies against CD43, CD62L, CD127, and CD69 in conjunction with anti-Ly5.1,
anti-CD8, and D
b/GP33 tetramers. FACS plots are gated on tetramer-binding Ly5.1





hi cells among tetramer-binding P14 CD8
+ T cells. C. IFN-c production by P14 cells from +/+ or IFNAR
2/2 mice were quantitated by
intracellular cytokine staining. Note that all Ly5.1
+ve P14 CD8
+ T cells from +/+ or IFNRA
2/2 mice produced IFN-c; the numbers are the MFI for IFN-c
staining. D. Granzyme B expression in P14 cells from +/+ or IFNAR
2/2 mice. Splenocytes were stained with anti-Ly5.1, anti-CD8, D
b/GP33 tetramers,
and anti-granzyme B; FACS histograms are gated on Ly5.1
+ve tetramer-binding CD8
+ T cells; dotted and solid lines show staining with isotype control
and anti-granzyme B antibodies respectively. E. Viral titers of liver, lung, and spleen from +/+ or IFNAR
2/2 mice were quantitated by plaque assay;
each symbol represents viral titer in an individual mouse. Results are representative of two independent experiments, with 3 to 4 mice per group.
doi:10.1371/journal.ppat.1000966.g009
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which is considered a key step in viral clearance. In our studies,
higher viral titers were attained upon infection of PKR-deficient
BMDCs with LCMV, as compared to wild type BMDCs.
Therefore, we propose that PKR
2/2 BMDCs have an intrinsic
defect in controlling LCMV replication. Apart from increased
virus production, PKR-deficient BMDCs showed less sustained
Type I IFN-induced suppression of LCMV replication in vitro.
Based on these findings, we propose that: 1) LCMV control by
innate defense mechanisms is at least in part dependent upon
PKR; 2) sustained suppression of LCMV replication by Type I
IFNs might include induction of PKR-dependent antiviral effects.
By contrast to the anti-viral effects, the effects of Type I IFNs on
CD8
+ T cells appear to be independent of PKR. Based on these
findings, we propose that distinct signaling pathways might
participate in mediating diverse functions of Type I IFNs.
It is well established that potent CD8
+ T cell memory is
necessary and sufficient to protect against an acute or persistent
LCMV infection [28]. However, it is unknown whether innate
immune mechanisms are important in viral control during the
secondary CD8
+ T cell responses. Immunocompetent mice
immunized with recombinant Listeria monocytogenes that expresses
the immunodominant LCMV CD8
+ T cell epitope GP33 (rLM-
GP33), is known to confer effective protective immunity against
LCMV [45]. We show that PKR
2/2 and IFNAR
2/2 mice
immunized with rLM-GP33 mounted potent secondary CD8
+ T
cell responses upon challenge with LCMV. Surprisingly, despite
the normal induction of secondary CTL responses, both PKR
2/2
and IFNAR
2/2 mice are unable to effectively control LCMV.
Impaired control of LCMV in rLM-GP33-immunized PKR
2/2
mice is likely due to a loss of PKR-dependent antiviral mechanism
in virus-infected cells because adoptively transferred wild type
TCR tg LCMV-specific memory CD8
+ T cells conferred
protective immunity in wild type mice, but not in PKR
2/2 or
Type I IFN receptor deficient (IFNAR
2/2) mice. Thus, PKR and
IFNAR signaling are required in infected cells, rather than in
CD8
+ T cells for control of LCMV infection during secondary
CD8
+ response. The number of memory CD8
+ T cells present at
the time of re-infection or challenge might regulate the role of
PKR or Type I IFNs in viral control during a secondary response.
Nevertheless, in the physiological setting of immunization with a
live LM vaccine, CD8
+ T cell memory is unable to effectively
control LCMV in the absence of PKR or Type I IFNs.
It is worth noting that LCMV titers in IFNAR
2/2 mice were
considerably greater than in PKR
2/2 mice, which suggests the
involvement of PKR-independent Type I IFN-triggered antiviral
mechanisms in LCMV control. It would be interesting to examine
protective immunity in LCMV in triple knockout mice lacking all
the major ISGs of Type I IFNs, PKR, RNase L, and Mx-1 [46].
As discussed before, GP33-specific CD8
+ memory T cells in
LM/GP33-immune IFNRA
2/2 mice showed normal expansion
and differentiation into effector cells, upon challenge with LCMV.
Interestingly, GP33-specific effector CD8
+ T cells in wild type but
not IFNRA
2/2 mice downregulated cell surface expression of
CD127, the IL-7 receptor. The inability of INFRA
2/2 deficient
CD8
+ T cells to downregulate CD127 expression could not be
linked to lack of direct effects of Type I IFNs because, adoptively
transferred donor IFNRA-sufficient GP33-specific memory P14
CD8
+ T cells also failed to downregulate CD127 expression in
LCMV-infected IFNRA
2/2 mice. These findings suggest that
Type I IFNs regulate CD127 expression on effector CD8
+ T cells
by indirect effects. It has been reported that cytokines like IL-6 and
IL-15 downregulate CD127 expression on CD8
+ T cells [47], and
importantly these cytokines are induced by Type I IFNs
[48,49,50,51,52,53]. Therefore, we speculate that defects in
induction of cytokines like IL-15 and/or IL-6 might impede
downregulation of CD127 expression on effector CD8
+ T cells in
IFNRA
2/2 mice. Notably, unlike challenge with LCMV, loss of
IFNRA signaling was not required for CD127 downregulation on
effector CD8
+ T cells upon challenge with vaccinia virus. These
findings suggest that infection with vaccinia virus but not LCMV
might induce factor(s) that downregulates CD127 expression in the
apparent absence of Type I IFNs, which in turn could be linked to
differences in pathogenesis including cell tropism of the virus and
the assortment of host responses elicited during infection.
Similar to LCMV infection, Type I IFNs play a critical role in
control of vaccinia virus infection; IFNAR
2/2 mice are highly
susceptible to vaccinia virus infection [25,26,54]. Interestingly,
however, unlike in an LCMV infection, Type I IFN signaling but
not PKR is required for control of vaccinia virus during secondary
CTL responses. These findings suggested that PKR-independent
mechanisms are important in vaccinia control by Type I IFNs.
The differential requirement for PKR in control of LCMV and
vaccinia virus is unknown. Only vaccinia virus and not LCMV is
known to encode proteins that antagonize the activation and/or
cellular function of PKR [14,55]. Therefore, the antiviral actions
of PKR are likely to be diminished in vaccinia-infected cells but
preserved in LCMV-infected cells. As a result, PKR deficiency
would be expected to have minimal effects on vaccinia virus
replication. It has to be noted that vaccinia virus also encodes
proteins to neutralize PKR-independent IFN actions [14,55],
which are obviously less effective in fully circumventing the anti-
viral effects of Type I IFNs, because deficiency of Type I IFNs
leads to impaired viral control [25,26,54].
In summary, we present new findings in this manuscript that
further our understanding of the cooperative interactions between
mechanisms of innate and adaptive immunity from the standpoint
of viral control and elicitation of virus-specific CD8
+ T cell
Figure 10. Secondary expansion of GP33-specific CD8





2/2 mice were immunized with rLM-GP33. A. GP33-specific memory CD8
+ T cells in LM-GP33-immune +/+, PKR
2/2 and
IFNAR
2/2 mice. At day 90 PI, the number of GP33-specific memory CD8 T cells in spleen was quantitated by intracellular cytokine staining. B.
Secondary expansion of GP33-specific CD8
+ T cells in spleen of +/+, PKR
2/2, and IFNRA
2/2 mice. At 90 days after immunization with LM-GP33, +/+,
PKR
2/2 and IFNAR
2/2 mice were challenged with recombinant vaccinia virus that expresses the glycoprotein of LCMV (VV-GP). Secondary expansion
of GP33-specific CD8
+ T cells was assessed in spleen five days after VV-GP challenge. Splenocytes were stained with anti-CD8, anti-CD44, and D
b/GP33
MHC I tetramers. Dot plots in B are gated on total CD8
+ T cells, and the numbers are the percentages of tetramer positive cells among total CD8
+ T
cells. C. Splenocytes from +/+, PKR
2/2 or IFNAR
2/2 recipients were stained with anti-CD8, anti-CD62L, anti-CD127, anti-KLRG-1, and D
b/GP33
tetramers. Dot plots are gated on tetramer-binding CD8
+ T cells, and the numbers are the percentages of cells in respective quadrants. D. Antigen-
triggered IFN-c production by CD8
+ T cells from +/+, PKR
2/2 or IFNAR
2/2 mice; dot plots are gated on total splenocytes, and the numbers are the
percentage of IFN-c producing cells amongst splenocytes. E. Granzyme B expression in GP33-specific CD8
+ T cells from +/+, PKR
2/2, or IFNAR
2/2
mice were measured by intracellular staining for granzyme B; histograms are gated on D
b/GP33- tetramer-binding CD8
+ T cells. Dotted and solid lines
show staining with isotype control and anti-granzyme B antibodies respectively. F. VV-GP titers in lung and ovary from +/+, PKR
2/2 or IFNAR
2/2 mice;
each symbol represents data from individual mice. Data is representative of or derived from two independent experiments, 3 to 4 mice per group.
doi:10.1371/journal.ppat.1000966.g010
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activity could be a distinguishing feature between Type I IFN
actions in mediating viral control versus CD8
+ T cell activa-
tion during an acute LCMV infection. Based on our studies we
propose that PKR controls LCMV replication by at least three
mechanisms: 1) augmenting innate antiviral mechanisms in infected
cells by promoting the expression of ISGs; 2) sustain Type I IFN-
induced antiviral actions in infected cells; 3) mediate a mechanism
of CD8
+ T cell-dependent viral control. Finally, we provide strong
evidence that vaccine-induced immunological memory is necessary
but not sufficient to provide protective immunity against viral
infection in the absence of PKR or Type I IFNs. These findings
have significant implications in understanding viral pathogenesis
and immune correlates of protection against viruses.
Materials and Methods
Mice
C57BL/6 mice were purchased from the National Cancer
Institute (Frederick, MD). RAG1
2/2 mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). Generation of PKR
deficient mice (PKR
2/2) on the C57BL/6 background were
described previously [56]. The IFNRA
2/2 mice on the C57BL/6
background [6] were provided by Dr. Kaja Murali-Krishna
(University of Washington, Seattle). All mice were used at 6-8
weeks of age according to the protocol V847 approved by the
University of Wisconsin School of Veterinary Medicine Institu-
tional Animal Care and Use Committee (IACUC). The animal
committee mandates that institutions and individuals using
animals for research, teaching, and/or testing must acknowledge
and accept both legal and ethical responsibility for the animals
under their care, as specified in the Animal Welfare Act (AWA)
and associated Animal Welfare Regulations (AWRs) and Public
Health Service (PHS) Policy.
Virus
Mice were infected intraperitoneally with 2610
5 PFU of the
Armstrong stain of LCMV [57]. Infectious LCMV in the tissues
was quantitated by a plaque assay using Vero cells [57]. The
recombinant vaccinia virus VV-GP that expresses the glycoprotein
of LCMV was provided by Lindsay Whitton (Scripps Research
Institute, La Jolla, CA) [58]. Mice were challenged with 2610
6
PFU of VV-GP by i.p. injection. VV-GP was quantitated by
plaque assay using CV-1 cells [58].
Listeria monocytogenes
Mice were infected with 5610
4 cfu of recombinant Listeria
monocytogenes that expresses the glycoprotein 33–41 epitope of
LCMV (rLM-GP33) by intravenous injection [45]. Bacterial load
in tissues was quantitated by plating tissue homogenates on brain-
heart infusion agar plates [45].
Cell surface staining and flow cytometry
The preparation and use of MHC I tetramers specific to the
LCMV epitopes nucleoprotein 396–404 (NP396) and glycoprotein
33–41 (GP33) have been described previously [59]. Splenocytes
were stained with fluorescent conjugated anti-CD8 (Clone 53–6.7),
anti-CD44 (Clone IM-7), and MHC I tetramers at 4 C for 1 h.
Cells were also stained with antibodies against CD43 (Clone
1B11), CD62L (Clone MEL-14), CD127 (Clone A7R34), and
CD69 (Clone H1.2F3) in conjunction with MHC I tetramers. In
some experiments splenocytes were stained with anti-Ly5.1 (Clone
A20) and anti- KLRG-1 (Clone 2F1) antibodies. To analyze
expression of Type I IFN receptors, peripheral blood mononuclear
cells were stained with anti-IFNAR antibodies (Clone MAR1-5A3;
Leinco Technologies, MO). Following staining, cells were fixed in
2% paraformaldehyde and samples were acquired with a
FACSCalibur flow cytometer (BD Biosciences, La Jolla, CA).
Intracellular staining for cytokines and granzyme B
Intracellular staining for IFN-c and TNF-a was performed as
described previously [59]. Briefly, freshly explanted splenocytes
(10
6 cells/well) were cultured with or without the LCMV epitope
peptides (0.1 ug/ml) in the presence of brefeldin A (Golgistop;
Pharmingen) and human recombinant interleukin-2 (10 U/well)
in 96-well flat-bottom plates. After 6 hours of in vitro stimulation,
cells were stained for surface CD8 and intracellular IFN-c (Clone
XMG1.2) and TNF-a (Clone MP6-XT22) using the cytofix/
cytoperm intracellular staining kit (BD Pharmingen). To stain for
granzyme B, splenocytes were first incubated with MHC I
tetramers, followed by permeabilization and staining for intracel-
lular granzyme B (Clone GB12; Caltag).
ELISA
IFN-a level in the mouse serum was measured with ELISA kit
(R & D Systems, Minneapolis, MN) as per the recommendations
of the manufacturer.
LCMV growth curve in BMDCs with or without treatment
with IFN-b
BMDCs were generated as described before [60]. Briefly, bone
marrow cells were collected from the tibias and femurs of +/+ or
PKR
2/2 mice. After RBC lysis, cells were resuspended at a
concentration of 10
6/ml and plated in 6-well plates in RPMI 1640
media containing 10% FBS and 20 ng/ml of murine GM-CSF
(PEPROTECH Inc, NJ). DCs were cultured for 6 days at 37C in
5% CO2 and half of the media containing GM-CSF was replaced
on days 2 and 4. On day 6, DCs were harvested for treatment with
IFN-b and infection with LCMV as follows. BMDCs (10
5/ml)
were plated onto 48-well plates and left untreated or treated with
IFN-b (R & D Systems, Minneapolis, MN) for 20 to 24 hours
before LCMV infection (MOI=0.01). The supernatant from each
well were collected for plaque assay.
RT-PCR
BMDCs described above were left untreated or treated with
1000 U/ml of IFN-b for 6 hours. Total RNA was extracted from
the BMDCs by using an RNA extraction kit (RNAqueous;
Ambion, Austin, TX). RNA was reverse transcribed to cDNA by
using Moloney murine leukemia virus reverse transcriptase from
Invitrogen (Carlsbad, CA). Equivalent amounts of cDNA (as
determined by 18S rRNA measurements by quantitative PCR)
were amplified in 35 cycles of PCR with SYBR green (Applied
Biosystems, Foster City, CA) by using primers designed for IRF-1,
IRF-3, IRF-5, and IRF-7, and analyzed by Applied Biosystems
7300 Real Time PCR System (Applied Biosystems, Foster City,
CA). Primer sets for IRF-1 were CAGCACTGTCACCGTGT-
GTCGT (forward) and GCGGCTTCGGAGGTGGAA (reverse),
IRF-3 were TGGGCAGCACAGCTGACATGA (forward) and
GCCCATTGCCCAGCCCTT (reverse), IRF-5 were CCTGCG-
CTGTGCCCTTAACA (forward) and TGTGGGAGCAGGG-
CCGTT (reverse) and IRF-7 were GCCTTGGGTTCCTGG-
ATGTGA (forward) and TGGGGCCATGGGGCTGTA (re-
verse). Relative expression ratio of the target gene was determined
based on 18S rRNA expression by using the following primer sets:
CGCCGCTAGAGGTGAAATTCT (forward) and CGAACCT-
CCGACTTTCGTTCT (reverse).
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YAC-1 target cells were obtained from a three day culture and
labeled with
51Cr. Splenocytes obtained from mice, infected with
LCMV three days before, were used as source of effector cells.
Effector and target cells were mixed at different ratios and the
supernatants were harvested after 5 hours.
51Cr release was
counted by a gamma counter and the percent lysis of target cells
by effector cells was calculated (Packard Instrument Company,
Meriden, CT).
Cytotoxicity assay
MHC class I restricted LCMV-specific cytotoxic activity in the
spleens was measured ex vivo by a standard
51Cr-release assay
using syngeneic LCMV peptide-pulsed MC57 cells as target cells
[57].
51Cr-labeled MC57 target cells were pulsed with LCMV
epitope peptides and mixed with effector (splenocytes) cells from
+/+ or PKR
2/2 mice at different indicated ratios. In some
experiments,
51Cr-labeled LCMV-infected primary BMDCs
derived from +/+ or PKR
2/2 mice were mixed with splenocytes
from B6 mice infected with LCMV. After 5 hours,
51Cr release
was quantified and the percent killing was calculated.
In vivo CTL assay
The MHC I restricted cytotoxic activity was assessed in vivo as
described previously [61]. Briefly, splenocytes from naı ¨ve +/+ or
PKR
2/2 mice were labeled with either 0.1 mMo r2mM of CFSE
(Molecular Probes, Eugene, OR). Splenocytes labeled with 2 mM
CFSE (CFSE
high) were pulsed with GP33 peptide (1 mg/ml) for
1 hour at 37C, whereas splenocytes labeled with 0.1 mM CFSE
(CFSE
low) were not pulsed with peptide. Equal proportions of
peptide-pulsed and unpulsed CFSE-labeled splenocytes were
mixed together and transferred to naı ¨ve or LCMV Arm-infected
mice by intravenous injection. Five hours later, the recipient mice
were euthanized and recovery of peptide-pulsed and unpulsed
target cells in spleens was quantified by flow cytometry. The
percent killing was calculated as follows: 100- {[(% peptide pulsed
in infected/% unpulsed in infected)/(% peptide pulsed in
uninfected/% unpulsed in uninfected)] X100}.




5 naı ¨ve Ly5.1/P14 CD8
+ T cells were adoptively
transferred into congenic C57BL/6/Ly5.2 mice. Twenty-four
hours after cell transfer, mice were infected with LCMV as above.
At least .100 days after infection, T cells were purified from the
spleens using T cell enrichment columns (R&D systems,
Minneapolis, MN) for adoptive transfer. Purified T cells
containing 2610
5 memory P14 TCR tg CD8
+ T cells were
adoptively transferred into +/+, PKR
2/2, or IFNRA
2/2 mice,
which were subsequently challenged with LCMV.
Immunofluorescent staining of tissues
Tissues were embedded in OCT compound and snap frozen
with liquid nitrogen. Frozen sections were cut with cryostat and
fixed with acetone at 4C, dried and stained with antibody
conjugated with fluorescent dye Alexa 568.
Statistical analysis
The commercially available software (SYSTAT [Chicago, IL],
version 10.2) was used to analyze data. To analyze for differences
between groups, unpaired t test was performed at 95% confidence
interval. In some analyses, differences between groups were
compared by testing for the equality of the proportions of
detectable viral titers. Some statistical analyses were done using the
Prizm software also.
Supporting Information
Figure S1 LCMV clearance in RAG1-deficient mice. Groups of
wild type +/+ and RAG1-deficient (RAG1
2/2) mice were infected
with LCMV, and viral titers were quantitated by plaque assay;
each symbol represents data from an individual mouse. Data is
from one of two independent experiments.
Found at: doi:10.1371/journal.ppat.1000966.s001 (0.05 MB TIF)
Figure S2 CD8
+ T cell responses to LCMV in PKR-deficient
mice (day 5 PI). Groups of wild +/+ and PKR
2/2 mice were
infected with LCMV, and CD8
+ T cells that are specific to the two
immunodominant epitopes were quantitated in the spleen by using
MHC I tetramers. Data are the mean of 3–4 mice/group and
representative of two independent experiments.
Found at: doi:10.1371/journal.ppat.1000966.s002 (0.03 MB TIF)
Figure S3 IFN-b-induced suppression of LCMV replication in
+/+ and PKR
2/2 BMDCs. As described for Figure 3, BMDCs
from +/+ and PKR
2/2 mice were left untreated or pretreated
with the indicated levels of IFN-b for 20 to 24 hours, then infected
with LCMV at 0.01 MOI. The supernatants of triplicate cultures
were collected at the indicated time points and viral titers were
determined by plaque assay. The percent reduction of viral titer
following treatment with IFN-b, as compared to no treatment was
calculated for each dose at all time points.
Found at: doi:10.1371/journal.ppat.1000966.s003 (3.73 MB TIF)
Figure S4 Cell surface expression of Type I IFN receptors on
PKR
2/2 cells. Peripheral blood mononuclear cells from +/+,
IFNRA
2/2, and PKR
2/2 mice were stained with anti-CD8, anti-
CD4, anti-B220, and anti-Type I IFN receptor antibodies; cells
from IFNRA
2/2 are used as negative controls. Following staining,




+ cells was assessed by flow cytometry. The FACS
histograms showing staining for the Type I IFN receptor, are gated
on the indicated cell population. Data shown are from one of two
independent experiments.
Found at: doi:10.1371/journal.ppat.1000966.s004 (0.05 MB TIF)
Figure S5 Effector and central memory CD8
+ T cells in LCMV-
immune PKR
2/2 mice. Groups of +/+ and PKR
2/2 mice were
infected with LCMV. At 90 days after infection, splenocytes were
stained with anti-CD8, D
b/MHC I tetramers, and anti-CD62L.
The cell surface expression of CD62L on tetramer-binding CD8
+
T cells was assessed by flow cytometry. The data shows the
percentages of CD62L
lo (effector memory subset) cells amongst
epitope-specific CD8
+ T cells. Data are from one of two




Found at: doi:10.1371/journal.ppat.1000966.s005 (0.03 MB TIF)
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